0000000000640569

AUTHOR

Francesco Vaia

showing 3 related works from this author

COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2.

2020

ABSTRACT Background Little evidence on COVID‐19 in people living with HIV (PLWH) is currently available. Material and Methods We reported clinical and viro‐immunological data of all HIV‐positive patients admitted to our centre with COVID‐19 from March 1 to May 12,2020. Results Overall, five patients were included: all were virologically‐suppressed on antiretroviral therapy and CD4+ count was >350 cell/mm3 in all but two patients. Although all patients had evidence of pneumonia on admission, only one developed respiratory failure. SARS‐CoV‐2‐RNA was never detected from nasopharyngeal swabs in two patients, whereas, in the others, viral clearance occurred within a maximum of 43 days. IgG prod…

Malemedicine.medical_treatmentHIV InfectionsAntibodies ViralSeverity of Illness IndexImmunoglobulin GPiperazinesimmune responseSARS‐CoV‐20302 clinical medicine030212 general & internal medicinebiologyCoinfectionImmunosuppressionMiddle AgedInfectious DiseasesAnti-Retroviral AgentsCytokinesRNA ViralReverse Transcriptase Inhibitors030211 gastroenterology & hepatologyFemaleAntibodyHeterocyclic Compounds 3-RingRiskPyridonesShort CommunicationShort CommunicationsTransgender PersonsProinflammatory cytokine03 medical and health sciencesImmune systemCOVID‐19VirologySeverity of illnessOxazinesmedicineHumansHIV Integrase InhibitorsTenofovirbusiness.industrySARS-CoV-2medicine.diseaseHIV infectionVirologyAntibodies NeutralizingCD4 Lymphocyte CountImmunity HumoralCOVID-19 Drug TreatmentPneumoniaRespiratory failureImmunologybiology.proteinbusinessJournal of medical virology
researchProduct

GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults

2022

International audience; Safe and effective vaccines against coronavirus disease 2019 (COVID-19) are essential for ending the ongoing pandemic. Although impressive progress has been made with several COVID-19 vaccines already approved, it is clear that those developed so far cannot meet the global vaccine demand alone. We describe a COVID-19 vaccine based on a replication-defective gorilla adenovirus expressing the stabilized prefusion severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein named GRAd-COV2. We assessed the safety and immunogenicity of a single-dose regimen of this vaccine in healthy younger and older adults to select the appropriate dose for each age group…

2019-20 coronavirus outbreakCOVID-19 VaccinesSettore BIO/06Coronavirus disease 2019 (COVID-19)COVID-19 VaccineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)GorillaAdenoviridaeAdenovirus Vaccinesbiology.animalPandemicAnimalsHumansMedicineMESH: COVID-19MESH: AnimalsMESH: SARS-CoV-2AgedMESH: Adenovirus VaccinesMESH: AgedGorilla gorilla[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyMESH: HumansbiologyAnimalSARS-CoV-2business.industryMESH: Gorilla gorillaCOVID-19MESH: AdenoviridaeGeneral MedicineVirologyAdenovirus VaccineMESH: COVID-19 Vaccinesbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHuman
researchProduct

GRAd-COV2, a gorilla adenovirus based candidate vaccine against COVID-19, is safe and immunogenic in young and older adults

2021

AbstractSafe and effective vaccines against coronavirus disease 2019 (COVID-19) are urgently needed to control the ongoing pandemic. Although impressive progress has been made with several COVID-19 vaccines already approved, it is clear that those developed so far cannot meet the global vaccine demand. We have developed a COVID-19 vaccine based on a replication-defective gorilla adenovirus expressing the stabilized pre-fusion SARS-CoV-2 Spike protein, named GRAd-COV2. We aimed to assess the safety and immunogenicity of a single-dose regimen of this vaccine in healthy younger and older adults to select the appropriate dose for each age group. To this purpose, a phase 1, dose-escalation, open…

Pediatricsmedicine.medical_specialtybiologybusiness.industryImmunogenicityGorillaVaccinationRegimenAntigenbiology.animalPandemicbiology.proteinmedicineAntibodySeroconversionbusiness
researchProduct